Ramesh Panchangula

Biography

 Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates. Our success is rooted in four key elements: Our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners Our unique research and development pipeline of new investigational medicines in cancer, pain and immunology Our proprietary and proven science and technology approach that fuels our discovery efforts Our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients with debilitating diseases  

Research Interest

 Pharmacokinetics and Toxicology: Preclinical safety assessment plays a vital role in the seamless integration of early research to development. Our team of highly motivated, experienced and well-trained scientists have expertise in developing models to screen new entities for pharmacokinetic and toxicology profile. The group supports both the evaluation of candidates in the discovery stage and IND enabling studies, for both large and small molecules in the research pipeline. Pharmacodynamics: Our team of dedicated scientists has expertise in various therapeutic areas which include oncology, immunotherapy, inflammation and pain, providing analysis of both large and small molecules, to support Nektar's pipeline, from preclinical stage to the early development and clinical stages. Capabilities include screening novel chemical and biological entities using various cell based (functional and receptor assays) and ex vivo assays for the identification and optimization of potential lead compounds.